Molecular modelling studies of some 9-arylacridines to elucidate their possible roles in Topoisomerase I inhibition

International Journal of Integrative Biology

Volumn 2, Issue 1, 2008, Pages 8-14

  Bhowmik, S ^a   Bagchi, A ^a   Ghosh, R ^a  

^a UNIVERSITY OF KALYANI   (India)

Author keywords

9 arylacridines; Antitumor agents; Molecular docking; Molecular modelling; Topoisomerase I

Indexed keywords

9 ARYLACRIDINE; ACRIDINE; DNA TOPOISOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; DNA BINDING; DNA DRUG COMPLEX; DNA RECOMBINATION; DNA REPLICATION; DNA TRANSCRIPTION; DRUG DNA BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; MOLECULAR MODEL; PROTEIN DNA INTERACTION;

EID: 70350400588     PISSN: 09738363     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Adams A et al. (2004) Structure of 9-amino-(N-(2-dimethylamino) propyl) acridine-4-carboxamide bound to d (CGTACG)(2): a comparison of structures of d (CGTACG)(2) complexed with intercalators in the presence of cobalt. Acta Crystallogr. D. 60(Pt5): 823-828.
2. Auparakkitanon S et al. (2003) Antimalarial 9-anilinoacridine compounds directed at hematin, Antimicrobial agents and Chemotherapy. Antimicrob. Agents Chemother. 47(12): 3708-3712.
3. Cholody WM et al. (1992) Synthesis and activity against murine leukemias. J. Med. Chem. 35(2): 378-382.
4. Datta I et al. (1990) Studies on enamides. Part-4: Photochemical investigations of N-aroyldiphenylamines. Tetrahedron 46(1919): 6821-6830.
5. Dauber-Osguthorpe P et al. (1988) Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase trimethoprim, a drug receptor system. Proteins 4(1): 31-47.
6. Demeunynck M et al. (2001) Interest of acridine derivatives in anticancer chemotherapy, Current pharmaceutical design. Curr. Pharm. Des. 7(17): 1703-1724.
7. Gamage SA et al. (1999). Structure activity relationships for substituted bis (acridine-4-carboxamides): a new class of anticancer agents. J. Med. Chem. 42(13): 2383-2393.
8. Geci I et al. (2006) Synthesis of twisted intercalating nucleic acids possessing acridine derivatives. Thermal stability studies. Bioconjug. Chem. 17(4): 950-957.
9. Granzhan A et al. (2005) N-aryl-9-amino-substituted acridizinium derivatives as fluorescent "light-up" probes for DNA and protein detection. Org. Lett. 7(23): 5119-5122.
10. Harris CC (1996) Structure and function of p53 tumor supressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88(20): 1442-1455.
11. Hisiang YH et al. (1985) Camtothecin induces protein linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260(27): 14873-14878.
12. Hornedo J et al. (1985) Amsacrine[m-AMSA]: a new antineoplastic agent. Pharmacology, clinical activity and toxicity. Pharmacotherapy 5(2): 78-90.
13. Joseph J et al. (2003) Design of photoactivated DNA oxidizing agents: synthesis and study of photophysical properties and DNA interactions of novel viologen linked acridines. Chemistry 9(23): 5926-5935.
14. Joseph J et al. (2004) Tuning of intercalation and electron-transfer processes between DNA and acridinium derivatives through steric effects. Bioconjug. Chem. 15(6): 1230-1235.
15. Kohn KW (1996) Beyond DNA cross-linking: history and prospects of DNA targeted cancer treatment-fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 56(24): 5533-5546.
16. Leopold WR et al. (1985) Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res. 45(11Pt1): 5532-5539.
17. Li TK Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41: 53-77.
18. LoRusso P et al. (1990) Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res. 50(16): 4900-4905.
19. Mathijssen RH et al. (2002) Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2(2): 103-123.
20. Nitiss JL (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta. 1400(1-3): 63-82.
21. Pommier Y et al. (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage site. Proc. Natl. Acad. Sci. U.S.A. 92(19): 8861-8865.
22. Rajendran A et al. (2006) Unprecedented dual binding behaviour of acridine group of dye: a combined experimental and theoretical investigation for the development of anticancer chemotherapeutic agents. Biochim. Biophys. Acta. 1760(12): 1794-1801.
23. Redinbo MR et al. (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279(5356): 1504-1513.
24. Rodriquez-Galindo C et al. (2000) Clinical use of topoisomerase I inhibitors in anticancer treatment. Med. Pediatr. Oncol. 35(4): 385-402.
25. Schneidman-Duhovny D et al. (2003) Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 52(1): 107-112.
26. Staker BL et al. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. U.S.A. 99(24): 15387-15392.
27. Staker BL et al. (2005) Structure of three classes of anticancer agents bound to human topoisomerase I-DNA covalent complex. J. Med. Chem. 48(7): 2336-2345.
28. Stewart L et al. (1996) The domain organization of human topoisomerase I. J. Biol. Chem. 271(13): 7602-7608.
29. Stewart L et al. (1998) A model for the mechanism of human topoisomerase I. Science 279(5356): 1534-1541.
30. Sordet O et al. (2003) Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents 3(4): 271-290.
31. Thompson J et al. (1998) Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys. Acta. 1400 (1-3): 301-319.
32. Ulukan H and Swaan PW (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs 62(14): 2039-2057.
33. Wang JC (1991) DNA Topoisomerase: Why So Many? J. Biol. Chem. 266(11): 6659-6662.
34. Wang JC (1996) DNA topoisomerases. Annu. Rev. Biochem. 65: 635-692.
35. Wesierska-Gadek J et al. (2004) Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumour triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res. 64(13): 4487-4497.
36. Zee-Chenq RK et al. (1978) Antineoplastic agents. Structure-activity relationship study of bis (substituted aminoalkylamino) anthraquinones. J. Med. Chem. 21(3): 291-294.